尤瑞克林联合依达拉奉治疗急性脑梗死的临床疗效及对血清VEGF和NO的影响

目的:观察尤瑞克林联合依达拉奉治疗急性脑梗死的临床疗效及对血清血管内皮生长因子(vascular endothelial growth factor,VEGF)和一氧化氮(nitric oxide,NO)的影响。方法:将2015年1月至2016年12月期间在我院神经内科住院治疗的急性脑梗死患者70例随机分成观察组和对照组。两组患者均采用常规治疗方式,如抗血小板、脑保护、活血化瘀等。在此基础上,给予观察组患者依达拉奉和尤瑞克林治疗,而对照组仅给予依达拉奉治疗,两组患者均持续治疗10 d。随后,分别观察两组患者的临床疗效以及治疗前后的血清VEGF和NO水平变化。结果:观察组的总有效率明显高于对照组,且差异具有统计学意义(P0.05);治疗后,两组患者的血清VEGF和NO水平均较治疗前明显升高,NIHSS评分明显下降(P0.05),且观察组的血清VEGF和NO水平均显著高于对照组,NIHSS评分明显低于对照组差异(P0.05)。结论:采用尤瑞克林联合依达拉奉治疗急性脑梗死的临床疗效优于依达拉奉单药治疗,可能与其明显提高血清血清VEGF、NO水平,有助于改善患者的血管内皮细胞功能和神经功能缺损有关。

Therapeutic Effect of Urinary Kallidinogenase Combined with Edaravone on the Patients with Acute Cerebral Infarction and on the Sserum VEGF and NO Levels

ABSTRACT Objective: To observe the therapeutic effect of urinary kallidinogenase combined with edaravone on the patients with acute cerebral infarction and the serum vascular endothelial growth factor(VEGF) and nitric oxide (NO) levels. Methods: 70 patients with acute cerebral infarction treated in our hospital from January 2015 to December 2016 were chosen and randomly divided into the observation group and the control group with 35 cases in each groups. All the patients were given conventional therapy, such as antiplatelet, brain protection, activating blood circulation to dissipate blood stasis and so on. In addition, patients in the observation group were given edaravone and urinary kallidinogenase, while patients in the control group were given edaravone alone. Both groups were treated for 10 days. Then the therapeutic effect and changes of NIHSS, VEGF, NO levels before and after treatment were compared between two groups. Results: The total effective rate of patients in the observation group was higher than that of the control group(P<0.05). The serum VEGF and NO levels of both groups were increased after treatment (P<0.05), while the NIHSS were significantly decreased(P<0.05). The VEGFand NO levels of observation group were higher than those of control group after treatment (P<0.05), the NIHSS of observation group was much lower than that of the control group after treatment (P<0.05). Conclusion: Urinary kallidinogenase combined with edaravone was more effective than edaravone alone in the treatment of patients with acute cerebral infarction, it might be related to the increase of serum VEGF and NO levels.